A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

NCT05087992 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Cancer, Metastatic

Interventions

DRUG: BI 905711
DRUG: FOLFIRI
DRUG: Bevacizumab

Sponsor

Boehringer Ingelheim